FinZonalExplore Data →
← CompaniesCOMPANY FINANCIAL PROFILE

BRISTOL MYERS SQUIBB CO

BMY · CIK 0000014272 · Pharmaceutical Preparations

Last SEC sync: Nov 7, 2026 19:21 UTC

About BRISTOL MYERS SQUIBB CO

In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.

Business information sourced from SEC annual filing filed Feb 11, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.

Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.

Financial highlights

Latest qualifying annual SEC observations · USD
Revenue$48.19BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Net Income$7.05BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Operating Income—Not available
Total Assets$90.04BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Total Liabilities$71.53BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Cash and Cash Equivalents$10.21BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Operating Cash Flow$14.16BPeriod Dec. 31, 2025 · 10-K · Filed Feb. 11, 2026
Revenue growth · latest comparable annual periods-0.2%
Net profit margin · matching fiscal period14.6%

Historical financial performance

USD billions · Annual SEC observations · Choose a metric

Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.

Annual financial history

USD · Exact fiscal period ends
Period endedRevenueNet incomeOperating incomeAssetsLiabilitiesCashOperating cash flowNet margin
Dec. 31, 2025$48.19B$7.05B—$90.04B$71.53B$10.21B$14.16B14.6%
Dec. 31, 2024$48.30B−$8.95B—$92.60B$76.22B$10.35B$15.19B-18.5%
Dec. 31, 2023$45.01B$8.02B—$95.16B$65.67B$11.46B$13.86B17.8%
Dec. 31, 2022$46.16B$6.33B—$96.82B$65.70B$9.12B$13.07B13.7%
Dec. 31, 2021$46.38B$6.99B—$109.31B$73.31B$13.98B$16.21B15.1%
Dec. 31, 2020$42.52B−$9.02B—$118.48B$80.60B$14.55B$14.05B-21.2%
Sept. 30, 2020———$125.54B—$19.44B——
June 30, 2020———$128.08B—$19.93B——

A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.

Company information

Registered name
BRISTOL MYERS SQUIBB CO
Ticker symbol
BMY
CIK
0000014272
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC SIC code
2834
Fiscal year end (MMDD)
1231
Last SEC synchronization
Nov 7, 2026 19:21 UTC
Headquarters / business address
ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543
Mailing address
ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543
Business phone
6092524621

Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:26 UTC. Official website, business descriptions and executive details require separate verification.

Latest SEC filings

Browse filings →
FormFiledReport periodOfficial source
10-QOct. 29, 2026Sept. 30, 2026View SEC filing ↗
10-QJuly 30, 2026June 30, 2026View SEC filing ↗
10-QApril 30, 2026March 31, 2026View SEC filing ↗
10-QOct. 30, 2025Sept. 30, 2025View SEC filing ↗
10-QJuly 31, 2025June 30, 2025View SEC filing ↗
10-QApril 24, 2025March 31, 2025View SEC filing ↗
10-QOct. 31, 2024Sept. 30, 2024View SEC filing ↗
10-QJuly 26, 2024June 30, 2024View SEC filing ↗
10-QApril 25, 2024March 31, 2024View SEC filing ↗
10-QOct. 26, 2023Sept. 30, 2023View SEC filing ↗
10-QJuly 27, 2023June 30, 2023View SEC filing ↗
10-QApril 27, 2023March 31, 2023View SEC filing ↗
10-QOct. 26, 2022Sept. 30, 2022View SEC filing ↗
10-QJuly 27, 2022June 30, 2022View SEC filing ↗
10-QApril 29, 2022March 31, 2022View SEC filing ↗
10-QOct. 27, 2021Sept. 30, 2021View SEC filing ↗
10-QJuly 28, 2021June 30, 2021View SEC filing ↗
10-QApril 29, 2021March 31, 2021View SEC filing ↗
10-QNov. 5, 2020Sept. 30, 2020View SEC filing ↗
10-QAug. 6, 2020June 30, 2020View SEC filing ↗

Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.